Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions

BACKGROUND: We tested the hypothesis that BRCA1/2 mutation carriers with ovarian cancer are at higher risk of carboplatin hypersensitivity reactions (HSRs). METHODS: Medical records of women enrolled in two carboplatin+olaparib clinical trials (NCT01237067/NCT01445418) were reviewed. A maximum of ei...

Descripción completa

Detalles Bibliográficos
Autores principales: Moon, D H, Lee, J-M, Noonan, A M, Annunziata, C M, Minasian, L, Houston, N, Hays, J L, Kohn, E C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Genetics and Genomics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749564/
https://www.ncbi.nlm.nih.gov/pubmed/23867999
http://dx.doi.org/10.1038/bjc.2013.389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749564/
https://www.ncbi.nlm.nih.gov/pubmed/23867999
http://dx.doi.org/10.1038/bjc.2013.389

Ejemplares similares